Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420732
Status:
TERMINATED
Last Update Posted:
2020-05-28
First Post:
2007-01-08
Brief Title:
Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer
Sponsor:
NewLink Genetics Corporation
Organization:
Lumos Pharma
Study Overview
Official Title:
A Phase II Study of Tergenpumatucel-L HyperAcute Lung Cancer Vaccine in Subjects With Advanced Non-Small Cell Lung Cancer Who Responded to First Line Platinum-Doublet Treatment
Status:
TERMINATED
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Enrollment goals unable to be reached
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the response rate of the administration of HyperAcute-Lung Cancer Vaccine for subjects with stage IIIB or stage IV non-small cell lung cancer who have been treated with first line platinum-doublet therapy and have responded or are considered to have stable disease
Detailed Description:
Unfortunately despite the best clinical efforts and breakthroughs in biotechnology most patients diagnosed with advanced stage lung cancer continue to die from their disease Reasons for this include that 1 patients are often diagnosed at a time when their lung cancer has already spread to other sites such as the chest cavity bone lung liver and brain limiting the options for local radiation therapy and surgery and 2 the cancer cells are resistant or become resistant to chemotherapy drugs used to treat the patient Resistance to one type of chemotherapy agent often rapidly leads to resistance against many other chemotherapy drugs
These reasons are the major causes of cancer progression that are usually discussed when considering treatment options for patients with disease that continues to grow and spread However another important part of the body should be considered-- the immune system Scientists have clearly shown that lung cancer cells produce a number of abnormal proteins or abnormal amounts of certain proteins found in normal lung cells Normally one would expect a patient to develop an immune response against these abnormal proteins found in their cancer and attack them much the way we would fight off an infection from a foreign bacteria or virus However for reasons that scientists do not fully understand the immune system fails to respond to these abnormal proteins and does not attack the lung cancer cells This human clinical trial proposes a new way to make the immune system recognize the cancer and encourage it to attack the cancer cells
Many people are familiar with the idea of transplants between people of organs like the kidneys or heart When an organ transplant between two people is completed one of the problems that can occur is rejection of the donated organ by the recipient This can occur because the immune system of the patient who receives the organ attacks the donated organ If you were to attempt to transplant a pig heart to a human the rejection would be dramatically stronger than when organs are transplanted between two people This is partly because lower animals express sugar-protein patterns on the surface of their cells that humans do not In fact our immune systems can quickly recognize tissues from lower mammals such as the pig or the mouse and destroys them
In this project we have put a mouse gene into human lung cancer cells that produces these abnormal sugar patterns and stimulates the immune system to attack the lung cancer This strategy works well to kill human other cancer cells in the laboratory but it needs to be tried in lung cancer patients to see if it will be effective and to determine if such a treatment causes any side effects We propose to test this new treatment in subjects with non-small cell lung cancer to see if it can stop slow or destroy tumors in these subjects Subjects will be injected with an anti-tumor vaccine consisting of a mixture of three types of dead human lung cancer cells that have been genetically altered to express the mouse gene responsible for making this abnormal sugar-protein on the cells
These reasons are the major causes of cancer progression that are usually discussed when considering treatment options for patients with disease that continues to grow and spread However another important part of the body should be considered-- the immune system Scientists have clearly shown that lung cancer cells produce a number of abnormal proteins or abnormal amounts of certain proteins found in normal lung cells Normally one would expect a patient to develop an immune response against these abnormal proteins found in their cancer and attack them much the way we would fight off an infection from a foreign bacteria or virus However for reasons that scientists do not fully understand the immune system fails to respond to these abnormal proteins and does not attack the lung cancer cells This human clinical trial proposes a new way to make the immune system recognize the cancer and encourage it to attack the cancer cells
Many people are familiar with the idea of transplants between people of organs like the kidneys or heart When an organ transplant between two people is completed one of the problems that can occur is rejection of the donated organ by the recipient This can occur because the immune system of the patient who receives the organ attacks the donated organ If you were to attempt to transplant a pig heart to a human the rejection would be dramatically stronger than when organs are transplanted between two people This is partly because lower animals express sugar-protein patterns on the surface of their cells that humans do not In fact our immune systems can quickly recognize tissues from lower mammals such as the pig or the mouse and destroys them
In this project we have put a mouse gene into human lung cancer cells that produces these abnormal sugar patterns and stimulates the immune system to attack the lung cancer This strategy works well to kill human other cancer cells in the laboratory but it needs to be tried in lung cancer patients to see if it will be effective and to determine if such a treatment causes any side effects We propose to test this new treatment in subjects with non-small cell lung cancer to see if it can stop slow or destroy tumors in these subjects Subjects will be injected with an anti-tumor vaccine consisting of a mixture of three types of dead human lung cancer cells that have been genetically altered to express the mouse gene responsible for making this abnormal sugar-protein on the cells
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| OBA0611-820 | OTHER | Office of Biotechnology Activities | None |